Hemab Therapeutics to Present New Preclinical Data on HMB-001 in Factor VII Deficiency and Initial Findings from Glanzmann Thrombasthenia Natural History Study at the International Society on Thrombosis and Haemostasis (ISTH) 2023 Congress

Posted on by

HMB-001 is currently in Phase 1/2 clinical study for Glanzmann Thrombasthenia—early research supports its potential expansion into Factor VII Deficiency COPENHAGEN, Denmark and BOSTON, June 15, 2023 /PRNewswire/ — Hemab Therapeutics, a clinical-stage biotechnology company developing the…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.